Bank of America Corp DE Buys 1,982 Shares of Deciphera Pharmaceuticals Inc (DCPH)

Bank of America Corp DE lifted its stake in shares of Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) by 316.1% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,609 shares of the company’s stock after purchasing an additional 1,982 shares during the period. Bank of America Corp DE’s holdings in Deciphera Pharmaceuticals were worth $103,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the company. FMR LLC boosted its holdings in shares of Deciphera Pharmaceuticals by 33.5% during the 2nd quarter. FMR LLC now owns 1,182,091 shares of the company’s stock worth $46,515,000 after purchasing an additional 296,571 shares during the last quarter. BlackRock Inc. lifted its holdings in Deciphera Pharmaceuticals by 18.2% in the second quarter. BlackRock Inc. now owns 591,064 shares of the company’s stock valued at $23,258,000 after acquiring an additional 91,185 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Deciphera Pharmaceuticals in the second quarter valued at approximately $21,989,000. Vivo Capital LLC acquired a new position in Deciphera Pharmaceuticals in the second quarter valued at approximately $9,953,000. Finally, Laurion Capital Management LP acquired a new position in Deciphera Pharmaceuticals in the second quarter valued at approximately $6,019,000. Institutional investors and hedge funds own 56.00% of the company’s stock.

DCPH opened at $26.07 on Monday. Deciphera Pharmaceuticals Inc has a one year low of $15.15 and a one year high of $45.61. The company has a market capitalization of $981.82 million, a P/E ratio of -8.72 and a beta of 3.79. The company has a debt-to-equity ratio of 0.06, a quick ratio of 18.46 and a current ratio of 18.46.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.65) EPS for the quarter, meeting analysts’ consensus estimates of ($0.65). As a group, analysts anticipate that Deciphera Pharmaceuticals Inc will post -2.62 EPS for the current year.

A number of research firms recently commented on DCPH. BidaskClub upgraded Deciphera Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, September 25th. Leerink Swann began coverage on Deciphera Pharmaceuticals in a report on Monday, September 24th. They issued an “underperform” rating and a $28.00 price objective on the stock. Raymond James began coverage on Deciphera Pharmaceuticals in a report on Wednesday, August 29th. They issued an “outperform” rating and a $47.00 price objective on the stock. Cantor Fitzgerald began coverage on Deciphera Pharmaceuticals in a report on Wednesday, August 22nd. They issued an “overweight” rating and a $53.00 price objective on the stock. Finally, Canaccord Genuity began coverage on Deciphera Pharmaceuticals in a report on Tuesday, August 7th. They issued a “buy” rating and a $55.00 price objective on the stock. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company’s stock. Deciphera Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $43.11.

WARNING: “Bank of America Corp DE Buys 1,982 Shares of Deciphera Pharmaceuticals Inc (DCPH)” was posted by Community Financial News and is the sole property of of Community Financial News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2018/12/03/bank-of-america-corp-de-buys-1982-shares-of-deciphera-pharmaceuticals-inc-dcph.html.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

See Also: Market Capitalization, Large-Caps, Mid-Caps, Small-Caps

Institutional Ownership by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit